PRAXIS PRECISION MEDICINES, INC.

(PRAX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/13/2022 05/16/2022 05/17/2022 05/18/2022 05/19/2022 Date
10.35(c) 10.92(c) 10.95(c) 10.11(c) 10.26 Last
624 125 1 656 735 551 762 318 403 319 485 Volume
+14.11% +5.51% +0.27% -7.67% +1.48% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -256 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,85x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -260 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,01x
Yield 2023 -
Capitalization 452 M 452 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 139
Free-Float 99,5%
More Financials
Company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating genetic insights into the development of therapies for central nervous system (CNS) disorders. Its portfolio of CNS programs is structured by therapeutic focus in three primary franchises, which include Psychiatry, Movement Disorders, and Epilepsy. It has three product candidates, which include the PRAX-114,... 
More about the company
Ratings of Praxis Precision Medicines, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about PRAXIS PRECISION MEDICINES, INC.
05/18TRANSCRIPT : Praxis Precision Medicines, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel ..
CI
05/11TRANSCRIPT : Praxis Precision Medicines, Inc. Presents at Bank of America 2022 Healthcare ..
CI
05/11Praxis Precision Medicines to Present at Upcoming Investor Conferences
AQ
05/10Wedbush Adjusts Price Target on Praxis Precision Medicines to $34 From $40, Keeps Outpe..
MT
05/09TRANSCRIPT : Praxis Precision Medicines, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09PRAXIS PRECISION MEDICINES, INC. Management's Discussion and Analysis of Financial Con..
AQ
05/09PRAXIS PRECISION MEDICINES, INC. : Results of Operations and Financial Condition, Regulati..
AQ
05/09Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Stud..
AQ
05/09Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Fin..
AQ
05/09Praxis Precision Medicines, Inc. Reports Earnings Results for the First Quarter Ended M..
CI
05/09Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Stud..
CI
05/04Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
AQ
05/02Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Fi..
AQ
04/29PRAXIS PRECISION MEDICINES, INC. : Other Events (form 8-K)
AQ
04/29Praxis Precision Medicines, Inc. Receives Email Communication from U.S. Food and Drug A..
CI
More news
News in other languages on PRAXIS PRECISION MEDICINES, INC.
05/09Praxis Precision Medicines annonce des résultats préliminaires positifs de l'étude de p..
05/09Praxis Precision Medicines, Inc. annonce ses résultats pour le premier trimestre clos l..
04/29Praxis Precision Medicines, Inc. reçoit une communication par courriel de la Food and D..
02/28Praxis Precision Medicines affiche une perte plus importante au quatrième trimestre
02/28Praxis Precision Medicines, Inc. annonce ses résultats pour l'année complète se termina..
More news
Analyst Recommendations on PRAXIS PRECISION MEDICINES, INC.
More recommendations
Chart PRAXIS PRECISION MEDICINES, INC.
Duration : Period :
Praxis Precision Medicines, Inc. Technical Analysis Chart | PRAX | US74006W1080 | MarketScreener
Technical analysis trends PRAXIS PRECISION MEDICINES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 10,11 $
Average target price 44,48 $
Spread / Average Target 340%
EPS Revisions
Managers and Directors
Marcio Souza President, Chief Executive Officer & Director
Timothy Edwin Kelly Chief Financial Officer & Treasurer
Dean Jonathan Mitchell Chairman
Bernard Ravina Chief Medical Officer
Steven Petrou Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PRAXIS PRECISION MEDICINES, INC.-48.68%452
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524